Is Kodiak Sciences going out of business?

KODIAK SCIENCES INC. (KOD) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

KODIAK SCIENCES INC. (KOD) scores 29 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Return on Assets: -89.55%

Five questions, kept separate

Survival - Fragile

9-13 mo of estimated runway from 2026-06-30, based on $126M of cash and short-term investments against $137M of annual burn. Adjusted shares outstanding increased 18.0% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Balanced

4.3% net-cash backing support a balanced pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Debt / Equity: -1.20x (Net Cash)
• Return on Assets: -89.55%
• Price / Earnings: Unprofitable (see Valuation)
• Cash Runway (years): 0.92y
• Shares dilution YoY: 17.97% (YoY)
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-08-13.

Price as of 2026-09-07.